Divi's Laboratories (DIVISLAB) — Announcement

Divi's Laboratories received a Draft Assessment Order from the Income Tax Authority for FY2022-23 proposing ₹570.51 crores in additions/disallowances related to transfer pricing adjustments on domestic transactions and corporate tax adjustments. The company faces potential additional income tax liability and separate penalty proceedings under Section 270A for alleged income underreporting. Management plans to evaluate and file an appeal within the stipulated timeframe.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DIVISLAB ✨ Ask AI About This

About Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,79,470.03 Cr P/E: 72.4 ROE: 16.6% ROCE: 22.1%

View full DIVISLAB stock details →

📡 Get AI alerts when DIVISLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DIVISLAB — Free

💡 Ask AI about this filing

"How does this announcement affect Divi's Laboratories Limited's outlook?" "What did Divi's Laboratories Limited announce on 21 March 2026?" "Is this positive or negative for DIVISLAB?"

Ask AI Free →

📊 More DIVISLAB filings

See all DIVISLAB filings →

🔥 Also filed on 21 March 2026

DELHIVERY Delhivery Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.